The Development and Outcome of Acute-on-Chronic Liver Failure After Surgical Interventions.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
02 2020
Historique:
received: 13 06 2019
accepted: 12 10 2019
pubmed: 7 11 2019
medline: 19 3 2021
entrez: 7 11 2019
Statut: ppublish

Résumé

Acute-on-chronic liver failure (ACLF) is a syndrome with high short-term mortality. Precipitating events, including hemorrhage and infections, contribute to ACLF development, but the role of surgery remains unknown. We investigated the development of ACLF in patients with cirrhosis undergoing surgery. In total, 369 patients with cirrhosis were included in the study. The clinical and laboratory data were collected prior to and on days 1-2, 3-8, and 9-28, and at 3 and 12 months after surgery. Surgery type was classified as limited or extensive, as well as liver and nonliver surgery. A total of 39 patients had baseline ACLF. Surgery was performed during acute decompensation in 35% of the rest of the 330 patients, and 81 (24.5%) developed ACLF within 28 days after surgery. Surrogate markers of systemic inflammation were similar in patients who developed ACLF or not. Age, sex, serum sodium, baseline bacterial infection, and abdominal nonliver surgery were independent predictors for the development of ACLF after surgery. Patients who developed ACLF within 28 days after surgery had a higher mortality at 3, 6, and 12 months. Survival did not differ between patients with ACLF at surgery and those developing ACLF after surgery. Development of ACLF within 28 days after surgery and elevated alkaline phosphatase and international normalized ratio were independent predictors of 90-day mortality. Independent predictors of 1-year all-cause mortality were alkaline phosphatase, Model for End-Stage Liver Disease score, and preoperative hepatic encephalopathy, whereas nonliver surgery was associated with improved survival. ACLF frequently develops in patients with cirrhosis undergoing surgery, especially in those with active bacterial infection, lower serum sodium, and kidney or coagulation dysfunction. Prognoses of ACLF both at and after surgery are similarly poor. Patients with cirrhosis should be carefully managed perioperatively.

Identifiants

pubmed: 31693788
doi: 10.1002/lt.25675
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

227-237

Informations de copyright

Copyright © 2019 The Authors. Liver Transplantation published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases.

Références

Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016;2:16041.
European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-460.
Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al.; for CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-1437.
Trebicka J. Predisposing factors in acute-on-chronic liver failure. Semin Liver Dis 2016;36:167-173.
Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut 2017;66:541-553.
Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999;29:1617-1623.
Abbas N, Makker J, Abbas H, Balar B. Perioperative care of patients with liver cirrhosis: a review. Health Serv Insights 2017;10:1178632917691270.
Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology 2017;66:1232-1241.
Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243-252.
Fernández J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, et al.; for European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2018;67:1870-1880.
Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al.; for CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF). Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64:1249-1264.
Jansen C, Möller P, Meyer C, Kolbe CC, Bogs C, Pohlmann A, et al. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology 2018;67:1472-1484.

Auteurs

Leah Maria Klein (LM)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Johannes Chang (J)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Wenyi Gu (W)

Translational Hepatology, Department of Internal Medicine I, Goethe University Clinic Frankfurt, Frankfurt, Germany.
European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Steffen Manekeller (S)

Clinic for Surgery, University of Bonn, Bonn, Germany.

Christian Jansen (C)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Philipp Lingohr (P)

Clinic for Surgery, University of Bonn, Bonn, Germany.

Michael Praktiknjo (M)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Jörg C Kalf (JC)

Clinic for Surgery, University of Bonn, Bonn, Germany.

Martin Schulz (M)

Translational Hepatology, Department of Internal Medicine I, Goethe University Clinic Frankfurt, Frankfurt, Germany.

Ulrich Spengler (U)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Christian Strassburg (C)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Andrés Cárdenas (A)

GI/Liver Unit Hospital Clinic, University of Barcelona Institut d'Investigacions Biomèdiques August Pi-Sunyer, Barcelona, Spain.

Vicente Arroyo (V)

European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.

Jonel Trebicka (J)

Translational Hepatology, Department of Internal Medicine I, Goethe University Clinic Frankfurt, Frankfurt, Germany.
European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Institute for Bioengineering of Catalonia, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH